DiaMedica Therapeutics (DMAC) Invested Capital (2017)
DiaMedica Therapeutics' (DMAC) quarterly Invested Capital came in at $883000.0 in Q4 2017.
Powered by 
Analysis
DiaMedica Therapeutics (DMAC) Invested Capital (2017) Analysis & Trends
DiaMedica Therapeutics (DMAC) has reported Invested Capital for 1 consecutive years, with $883000.0 the latest figure, recorded in Q4 2017.
- For the quarter ending Q4 2017, Invested Capital changed N/A year-over-year to $883000.0; the trailing twelve-month figure through Dec 2017 stood at $883000.0 (changed N/A YoY), and the FY2017 full-year result was $883000.0, changed N/A from the prior year.
- Invested Capital was little changed at $883000.0 in Q4 2017 per DMAC's latest filing.
- Across five years, Invested Capital topped out at $883000.0 in Q4 2017 and bottomed at $883000.0 in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.47 Bn | 193.48 Bn | 7.24 Bn | 74.44 Bn |
| 2 | Gilead Sciences | 178.76 Bn | 175.58 Bn | 6.22 Bn | 40.49 Bn |
| 3 | Vertex Pharmaceuticals | 131.52 Bn | 123.67 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.91 Bn | 73.91 Bn | 3.93 Bn | 33.70 Bn |
| 5 | Argenx Se | 61.10 Bn | 55.91 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.44 Bn | 48.30 Bn | 52.00 Mn | 7.35 Bn |
| 7 | Alnylam Pharmaceuticals | 33.55 Bn | 30.24 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.67 Bn | 30.39 Bn | 1.96 Bn | 26.94 Bn |
| 9 | Roivant Sciences | 29.63 Bn | 29.63 Bn | 1.16 Mn | - |
| 10 | DiaMedica Therapeutics | 351.39 Mn | 351.39 Mn | - | - |